Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3339682 | Allergologia et Immunopathologia | 2014 | 8 Pages |
Abstract
Omalizumab promoted a global benefit on QoL and asthma control outcomes. It also yielded a reduction in asthma exacerbations and unscheduled health care visits, a steroid-sparing effect, and an improvement in lung function. The drug was found to be generally safe and well-tolerated.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
T. Vieira, J.F. de Oliveira, M. da Graça Castel-Branco,